{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T03:50:11Z","timestamp":1772250611737,"version":"3.50.1"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T00:00:00Z","timestamp":1713830400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Bispecific T-cell engager (TCE) therapies are revolutionising the treatment of several haematological malignancies, including B-cell acute lymphoblastic leukaemia, various subtypes of B-cell non-Hodgkin lymphoma, and multiple myeloma. Due to their unique mode of action in activating endogenous T cells, they are associated with several important early side effects, including cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. In addition, TCEs can cause target-specific toxicities and carry a significant risk of infection.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Currently, supportive care measures for TCEs have largely been inferred from other T-cell therapies, such as CAR-T (chimeric antigen receptor) therapy. Further research into TCE-specific supportive care measures is needed to improve the tolerability of these therapies for patients. A key question moving forward is understanding how to predict and minimise early toxicity (cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome). Associated infection risk is a significant cause of patient morbidity, therefore a better understanding of how to optimise TCE-dosing and prophylactic measures, such as intravenous immunoglobulin and antimicrobials, will be crucial to achieving an improved balance of toxicity and efficacy. Enabling early outpatient delivery of these therapies to select patients at lower risk of toxicity may also help to improve patient experience and quality of life.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Here we review up-to-date guidance and literature on existing supportive care measures for bispecific TCE therapy-related toxicities. We highlight both unique and serious side effects of TCE therapies that require improved management strategies to enable more patients to benefit from these efficacious drugs.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/spc.0000000000000699","type":"journal-article","created":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T16:02:29Z","timestamp":1713888149000},"page":"92-99","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Supportive care measures for bispecific T-cell engager therapies in haematological malignancies"],"prefix":"10.1097","volume":"18","author":[{"given":"Lucia Y.","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Haematology, MRC Weatherall Institute of Molecular Medicine, Oxford University, Oxford"},{"name":"Haematology Department, Oxford University Hospitals NHS Foundation Trust, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaimal","family":"Kothari","sequence":"additional","affiliation":[{"name":"Haematology Department, Oxford University Hospitals NHS Foundation Trust, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,4,23]]},"reference":[{"key":"R1-20250525","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"key":"R2-20250525","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.2021.0987","article-title":"Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia","volume":"325","author":"Locatelli","year":"2021","journal-title":"JAMA"},{"key":"R3-20250525","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/jama.2021.0669","article-title":"Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia","volume":"325","author":"Brown","year":"2021","journal-title":"JAMA"},{"key":"R4-20250525","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"key":"R5-20250525","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","article-title":"Phase II trial of the anti-CD19 bispecific T cell\u2013engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia","volume":"32","author":"Topp","year":"2014","journal-title":"J Clin Oncol"},{"key":"R6-20250525","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Evaluaci\u00f3n de la gravedad de los eventos adversos dermatol\u00f3gicos de las terapias antineopl\u00e1sicas","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermosifiliogr"},{"key":"R7-20250525","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.clml.2022.12.009","article-title":"Efficacy and safety of blinatumomab for the treatment of relapsed\/refractory acute lymphoblastic leukemia: a systemic review and meta-analysis","volume":"23","author":"Liu","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R8-20250525","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00277-018-3497-0","article-title":"Neurologic adverse events in patients with relapsed\/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors","volume":"98","author":"Stein","year":"2019","journal-title":"Ann Hematol"},{"key":"R9-20250525","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0140-6736(21)00889-8","article-title":"Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1\/2 study","volume":"398","author":"Hutchings","year":"2021","journal-title":"Lancet"},{"key":"R10-20250525","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J Clin Oncol"},{"key":"R11-20250525","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S2352-3026(22)00072-2","article-title":"Odronextamab, a human CD20\u00d7CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial","volume":"9","author":"Bannerji","year":"2022","journal-title":"Lancet Haematol"},{"key":"R12-20250525","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.21.00931","article-title":"Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study","volume":"40","author":"Budde","year":"2022","journal-title":"J Clin Oncol"},{"key":"R13-20250525","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1182\/blood-2021-147937","article-title":"Subcutaneous (SC) administration of mosunetuzumab with cycle 1 step-up dosing is tolerable and active in patients with relapsed\/refractory B-cell non-Hodgkin lymphomas (R\/R B-NHL): initial results from a phase I\/II study","volume":"138","author":"Bartlett","year":"2021","journal-title":"Blood"},{"key":"R14-20250525","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/hon.3174","article-title":"Glofitamab in relapsed\/refractory diffuse large B\u2010cell lymphoma: real\u2010world data","volume":"41","author":"Birtas Atesoglu","year":"2023","journal-title":"Hematol Oncol"},{"key":"R15-20250525","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"R16-20250525","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","article-title":"Teclistamab, a B-cell maturation antigen \u00d7 CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study","volume":"398","author":"Usmani","year":"2021","journal-title":"Lancet"},{"key":"R17-20250525","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1182\/blood-2022-162440","article-title":"Efficacy and safety of elranatamab in patients with relapsed\/refractory multiple myeloma na\u00efve to B-cell maturation antigen (BCMA)-directed therapies: results from cohort a of the magnetismm-3 study","volume":"140","author":"Bahlis","year":"2022","journal-title":"Blood"},{"key":"R18-20250525","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s12935-023-03045-y","article-title":"Safety and efficacy of T-cell-redirecting bispecific antibodies for patients with multiple myeloma: a systematic review and meta-analysis","volume":"23","author":"Noori","year":"2023","journal-title":"Cancer Cell Int"},{"key":"R19-20250525","doi-asserted-by":"crossref","first-page":"308.e1","DOI":"10.1016\/j.jtct.2023.12.016","article-title":"Safety and efficacy of teclistamab in patients with relapsed\/refractory multiple myeloma: a real-world experience","volume":"30","author":"Dima","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"R20-20250525","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1182\/blood-2023-191305","article-title":"Pooled analysis on bispecific antibody-related toxicities in multiple myeloma","volume":"142","author":"Golmohammadi","year":"2023","journal-title":"Blood"},{"key":"R21-20250525","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell\u2013redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"key":"R22-20250525","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41571-023-00735-4","article-title":"GPRC5D as a novel immunotherapeutic target in multiple myeloma","volume":"20","author":"Nath","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"R23-20250525","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1182\/blood-2021-147983","article-title":"Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed\/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study","volume":"138","author":"Trudel","year":"2021","journal-title":"Blood"},{"key":"R24-20250525","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J Immunother Cancer"},{"key":"R25-20250525","doi-asserted-by":"crossref","first-page":"eaax8861","DOI":"10.1126\/scitranslmed.aax8861","article-title":"CD3 bispecific antibody\u2013induced cytokine release is dispensable for cytotoxic T cell activity","volume":"11","author":"Li","year":"2019","journal-title":"Sci Transl Med"},{"key":"R26-20250525","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"R27-20250525","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","article-title":"Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network","volume":"24","author":"Ludwig","year":"2023","journal-title":"Lancet Oncol"},{"key":"R28-20250525","doi-asserted-by":"crossref","first-page":"6226","DOI":"10.1182\/blood-2012-01-400515","article-title":"Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell\u2013engaging CD19\/CD3-bispecific BiTE antibody blinatumomab","volume":"119","author":"Klinger","year":"2012","journal-title":"Blood"},{"key":"R29-20250525","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0140-6736(23)00521-4","article-title":"T-cell-engaging bispecific antibodies in cancer","volume":"402","author":"van de Donk","year":"2023","journal-title":"Lancet"},{"key":"R30-20250525","first-page":"2430","article-title":"How I treat refractory CRS and ICANS after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"R31-20250525","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"R32-20250525","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1182\/blood-2020-136980","article-title":"Early pharmacodynamic changes in T-cell activation, proliferation, and cytokine production confirm the mode of action of BFCR4350A, a FcRH5\/CD3 T-cell-engaging bispecific antibody, in patients with relapsed\/refractory multiple myeloma","volume":"136","author":"Nakamura","year":"2020","journal-title":"Blood"},{"key":"R33-20250525","doi-asserted-by":"crossref","first-page":"e000621","DOI":"10.1136\/jitc-2020-000621","article-title":"Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies","volume":"8","author":"Kauer","year":"2020","journal-title":"J Immunother Cancer"},{"key":"R34-20250525","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor\u2013modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"key":"R35-20250525","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev"},{"key":"R36-20250525","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.cell.2020.08.022","article-title":"Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies","volume":"183","author":"Parker","year":"2020","journal-title":"Cell"},{"key":"R37-20250525","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1182\/hematology.2023000508","article-title":"Bispecific antibody therapies","volume":"2023","author":"de Assis","year":"2023","journal-title":"Hematology"},{"key":"R38-20250525","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1007\/s00277-022-04889-6","article-title":"Thrombopoietin receptor agonist for treating bone marrow aplasia following anti-CD19 CAR-T cells\u2014single-center experience","volume":"101","author":"Beyar-Katz","year":"2022","journal-title":"Ann Hematol"},{"key":"R39-20250525","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1182\/blood-2023-181228","article-title":"Efficacy and safety of less frequent\/lower intensity dosing of talquetamab in patients with relapsed\/refractory multiple myeloma: results from the phase 1\/2 MonumenTAL-1 study","volume":"142","author":"Chari","year":"2023","journal-title":"Blood"},{"key":"R40-20250525","doi-asserted-by":"crossref","first-page":"10073","DOI":"10.1182\/blood-2022-163733","article-title":"Infections and severe hypogammaglobulinemia in multiple myeloma patients treated with anti-BCMA bispecific antibodies","volume":"140","author":"Lancman","year":"2022","journal-title":"Blood"},{"key":"R41-20250525","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.2022015956","article-title":"T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals","volume":"140","author":"Philipp","year":"2022","journal-title":"Blood"},{"key":"R42-20250525","doi-asserted-by":"crossref","first-page":"E349","DOI":"10.1002\/ajh.27071","article-title":"Increased risk of infection reporting with anti\u2010BCMA bispecific monoclonal antibodies in multiple myeloma: a worldwide pharmacovigilance study","volume":"98","author":"Contejean","year":"2023","journal-title":"Am J Hematol"},{"key":"R43-20250525","doi-asserted-by":"crossref","first-page":"906","DOI":"10.3324\/haematol.2023.283590","article-title":"The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma","volume":"109","author":"Hammons","year":"2023","journal-title":"Haematologica"},{"key":"R44-20250525","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41375-020-01016-0","article-title":"Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network","volume":"35","author":"Ludwig","year":"2021","journal-title":"Leukemia"},{"key":"R45-20250525","doi-asserted-by":"crossref","first-page":"e2238961","DOI":"10.1001\/jamanetworkopen.2022.38961","article-title":"Kinetics of humoral immunodeficiency with bispecific antibody therapy in relapsed refractory multiple myeloma","volume":"5","author":"Hammons","year":"2022","journal-title":"JAMA Netw Open"},{"key":"R46-20250525","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ccell.2022.03.013","article-title":"Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients","volume":"40","author":"Aleman","year":"2022","journal-title":"Cancer Cell"},{"key":"R47-20250525","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","article-title":"Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J"},{"key":"R48-20250525","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3389\/fimmu.2020.00524","article-title":"Diagnosis and management of secondary HLH\/MAS following HSCT and CAR-T cell therapy in adults; a review of the literature and a survey of practice within EBMT centres on behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP)","volume":"11","author":"Sandler","year":"2020","journal-title":"Front Immunol"},{"key":"R49-20250525","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s00520-023-08233-0","article-title":"Characterization of dysgeusia and xerostomia in patients with multiple myeloma treated with the T-cell redirecting GPRC5D bispecific antibody talquetamab","volume":"32","author":"Laheij","year":"2024","journal-title":"Supportive Care Cancer"}],"container-title":["Current Opinion in Supportive &amp; Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/SPC.0000000000000699","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T18:01:13Z","timestamp":1748196073000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/SPC.0000000000000699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,23]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/spc.0000000000000699","relation":{},"ISSN":["1751-4258"],"issn-type":[{"value":"1751-4258","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,23]]}}}